Journal Paper

Paper Information

Journal:
Year:0 | Volume: | Issue:
Start Page: | End Page:

video

sound

Persian Version

View:

8,109

Download:

0

Cites:

Information Journal Paper

Title

THE EFFECTS OF RESVERATROL SUPPLEMENTATION ON CARDIOVASCULAR RISK FACTORS IN SUBJECTS WITH NAFLD

Pages

 Start Page 110 | End Page 110

Keywords

NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) 

Abstract

 Background: RESVERATROL is a polyphenolic compound with antioxidant properties. RESVERATROL can prevent or slow down the progression of a wide variety of illnesses, including malignancies, neurodegenerative diseases, cardiovascular ailments, ischemic injury, and viral infections.No treatment has yet been approved for NAFLD, and the only recognized management strategies include lifestyle modifications. It has a strong association with central obesity, reduced glucose tolerance, type 2 diabetes mellitus, arterial hypertension and hypertriglyceridaemia.We evaluate whether supplementation with RESVERATROL can further improve the efficacy of lifestyle modifications and CARDIOVASCULAR RISK FACTORS on NAFLD patients.Methods: In this randomized double blinded controlled clinical trial, fifty NAFLD patients were supplemented with either a 500 mg RESVERATROL or a placebo capsule for 12 weeks. Both groups were advised to follow an energybalanced diet and physical activity recommendations.Fasting blood sugar, Insulin, lipid profile, Apo A1, hepatic steatosis, systolic blood pressure, diastolic blood pressure and, dietary intake, anthropometric measurements and physical activity were assessed at baseline and the end of the study. HOMA-IR, HOMA-b and QUICKI were calculated at baseline and the end of the study.Results: In both groups anthropometric measurements (weight, BMI, waist circumference), ALT, AST, GGT, HDL, steatosis grade improved (P-value<0.05); RESVERATROL supplementation was associated with a significant reduction in liver enzyme ALT, systolic blood pressure, and hepatic steatosis grade as compared to placebo supplementation (P-value<0.05). Total cholesterol in RESVERATROL group significantly increased as compared to placebo group. Fasting blood glucose did not change but serum insulin level in placebo group reduced. In placebo group HOMA-IR and HOMA- b decreased and QUICKI increased, but between groups differences was insignificant.Conclusion: 12 weeks of RESVERATROL supplementation in addition to lifestyle modification can improve some CARDIOVASCULAR RISK FACTORS. More research with longer duration and different dosage of supplementation are needed to confirm the present results.

Cites

  • No record.
  • References

  • No record.
  • Related Journal Papers

  • No record.
  • Related Seminar Papers

  • No record.
  • Related Plans

  • No record.
  • Recommended Workshops






    File Not Exists.